Cash cost of the wait: management is funding a defined waiting period whose end is already scheduled
The model's full reasoning — Q4 2023 call → NOThe question asks whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket — with three conditions: (1) paying now for something not yet earning, (2) management speaks as though the wait is the company's main current work, and (3) the far side is a specific, near-dated, already-visible event. Let me examine the transcript for evidence. Key candidates: - PL9643 MELODY-1 Phase III study in dry eye disease: fully enrolled, data expected before calendar year-end. This is a trial already paid for, waiting for data. But is the company "paying now" for something not yet earning? The trial costs are already incurred; the data is coming. The company is waiting for data, not paying ongoing costs for a facility or asset. The trial is complete (enrollment done), so the cost is largely sunk. The wait is for data readout, not for something being funded now. - PL8177 ulcerative colitis: on track to complete enrollment by year-end, interim data as early as year-end. Again, trial in progress, but this is ordinary R&D expense, not a "defined waiting period" where the company is carrying costs for something not yet earning. - PL9588 glaucoma: preclinical, regulatory discussions initiated, but not yet in trials. - Erectile dysfunction combination: planning to initiate clinical programs as early as end of this year. Not yet started. - Vyleesi: commercial product, already earning, growing. The question is looking for a situation where the company is currently bearing real, ongoing cash costs for something whose benefit hasn't arrived, and the end is a specific near-dated event. Looking at the transcript, the company talks about advancing programs, hitting milestones, expenses being higher due to program advancement. But this is standard R&D spending on clinical trials — the company is always paying for trials before data arrives. Is that "a defined waiting period it is paying for out of its own pocket"? The trials are being funded, and the data readouts are near-dated (year-end, Q1 2024). But is this described as "the company's main current work" in the sense of a gap it has chosen to stand in? The company describes multiple programs in parallel — Vyleesi is commercial and earning, dry eye trial is fully enrolled waiting for data, UC trial enrolling, kidney disease trial on track.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| LILA | Liberty Latin America Ltd. | Q4 2023 | 2024-02-23 | C |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| QTRX | Quanterix Corporation | Q3 2023 | 2023-11-07 | B |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| CDE | Coeur Mining, Inc. | Q1 2023 | 2023-05-11 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| EHTH | eHealth, Inc. | Q2 2021 | 2021-07-29 | F |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| YUM | Yum! Brands, Inc. | Q2 2018 | 2018-08-02 | C |
| IBTX | Independent Bank Group, Inc. | Q3 2017 | 2017-10-24 | A |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
SBS · Q3 2023 → YESThe question is whether management describes the company as currently living through a defined waiting period it's paying for out of its own pocket. YES The transcript shows management describing the company as currently bearing real, ongoing cash costs (salaries, consulting, transition work) for the IDP/restructuring program whose benefits (full expense reduction, shared-services center operational) are not yet realized. The far side is a specific, near-dated event: full 3.7% staff reduction and shared-services center operational by mid-2024 (July 2024 for full benefit), with the program already in motion and on schedule. Management frames this as the main current work, not a setback, and treats the costs as self-funded. This meets all three conditions.
EHTH · Q2 2021 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing the company as currently living through a defined waiting period for the AEP, paying for it out of its own pocket through heavy investments in internal agents and quality initiatives. They hired agents early, many still in training with lower productivity, and are bearing the cost of additional training and customer service expansion in Q3. This is framed as a chosen investment to improve enrollment quality and prepare for the fourth-quarter AEP, not an apology or external issue.
YUM · Q2 2018 → YESThe question is whether management describes the company as currently living through a defined waiting period it is paying for out of its own pocket. YES The transcript shows management describing a clear, self-funded transition cost tied to the refranchising effort. They explicitly call out the “timing mismatch between G&A savings and refranchising” as one of the four items weighing on Q2 core operating profit, and they quantify the full-year headwind at 6 7 percentage points. This is presented as a real, ongoing drag on current results while they complete the shift to 98 % franchised by year-end 2018 and reach the 1.7 % G&A run-rate target in 2019.